Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Core Insights - Solid Biosciences is advancing its pipeline with three clinical-stage programs targeting neuromuscular and cardiac diseases, including SGT-003 for Duchenne Muscular Dystrophy, SGT-212 for Friedreich's Ataxia, and SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia [2][4][9] Clinical Trials and Pipeline - The Phase 1/2 INSPIRE DUCHENNE trial has dosed 15 participants, with ongoing recruitment and no serious adverse events reported [1][3][5] - SGT-212 and SGT-501 are expected to initiate Phase 1b trials in Q4 2025, with SGT-212 being the first gene therapy for Friedreich's Ataxia utilizing a dual route of administration [1][4][6][9] - A randomized, double-blind, placebo-controlled trial for SGT-003 is planned outside the U.S. in Q4 2025 to support global regulatory authorizations [5] Financial Position - As of June 30, 2025, the company reported $268.1 million in cash and equivalents, providing a cash runway into H1 2027 [1][8] - Research and Development expenses for Q2 2025 were $32.4 million, up from $19.5 million in Q2 2024, primarily due to increased costs associated with SGT-003 [8][13] - The net loss for Q2 2025 was $39.5 million, compared to $25.1 million in Q2 2024, reflecting increased operational expenses [13][15] Strategic Partnerships and Technology - Solid has executed over 25 agreements for the use of its proprietary AAV-SLB101 capsid with academic labs and institutions [1][9] - The company is developing multiple next-generation capsid and promoter libraries, with the first cardiac capsid library selection expected in Q4 2025 [9] Market Position and Mission - Solid Biosciences is focused on improving the lives of patients with rare diseases, leveraging its expertise in genetic medicine to innovate therapies for conditions like Duchenne and Friedreich's Ataxia [2][11]